慢加急性肝衰竭的免疫治疗

韩英; 崔丽娜; 郭冠亚

doi:10.3969/j.issn.1001-5256.2017.09.010

慢加急性肝衰竭的免疫治疗

DOI: 10.3969/j.issn.1001-5256.2017.09.010

第四军医大学西京消化病医院

详细信息

中图分类号: R575.3
计量
- 文章访问数: 2527
- HTML全文浏览量: 30
- PDF下载量: 474
- 被引次数: 0
出版历程
- 收稿日期: 2017-06-21
- 出版日期: 2017-09-20

Immunotherapy for acute-on-chronic liver failure

Xijing Hospital of Digestive Disease, Fourth Military Medical University

摘要

摘要: 炎症反应和免疫功能紊乱在慢加急性肝衰竭的病程进展中发挥关键作用,导致全身炎症反应综合征,过度的炎症及免疫反应,导致感染易感性增加,最终出现多脏器功能衰竭(MODS)。消除肝损伤并纠正免疫紊乱可预防败血症和(或)MODS,改善患者的生存。迄今为止,ACLF的免疫治疗在各大治疗指南中尚未被推荐。然而,作为ACLF重要病理生理改变,并且与发病率、病死率密切相关的关键事件——肝脏局部和全身炎症反应持续激活及免疫细胞功能障碍,又促使我们不得不考虑免疫调节治疗,以阻断和逆转疾病的进展。因此,简述了目前应用于ACLF治疗的具有潜在免疫调节作用的药物,包括传统药物白蛋白、糖皮质激素等使用,粒细胞集落刺激因子、人工肝支持系统及间充质干细胞移植等的应用,并讨论了一些有希望的未来免疫治疗靶点。
- 肝功能衰竭 /
- 多器官功能衰竭 /
- 免疫疗法 /
- 治疗
Abstract: Inflammatory response and immune dysfunction play important roles in the progression of acute-on-chronic liver failure ( ACLF) and may lead to systemic inflammatory response syndrome. Excessive inflammatory and immune response may result in increased susceptibility to infection and finally lead to multiple organ dysfunction syndrome ( MODS) . Elimination of liver injury and correction of immune dysfunction can prevent sepsis and/or MODS and improve patients'survival. Up to now, immunotherapy for ACLF has not been recommended in related guidelines. However, as an important pathophysiological change of ACLF and a key event closely associated with incidence rate and mortality rate, persistent activation of hepatic and systemic inflammatory response and immune cell dysfunction urges us to consider immunoregulatory treatment, in order to block and reverse disease progression. This article introduces potential immunoregulatory drugs for the treatment of ACLF, including albumin, glucocorticoids, granulocyte colony-stimulating factor, artificial liver support system, and mesenchymal stem cell transplantation, and discusses some promising targets for immunotherapy.
- liver failure /
- multiple organ failure /
- immunotherapy /
- therapy

HTML全文

参考文献(28)

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, CMA.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[2]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.

[3]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterology, 2013, 144 (7) :1426-1437, 1437.e1-9.

[4] SARIN SK, CHOUDHURY A.Acute-on-chronic liver failure:terminology, mechanisms and management[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (3) :131-149.

[5]XING T, LI L, CAO H, et al.Altered immune function of monocytes in different stages of patients with acute on chronic liver failure[J].Clin Exp Immunol, 2007, 147 (1) :184-188.

[6]MOOKERJEE RP, STADLBAUER V, LIDDER S, et al.Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome[J].Hepatology, 2007, 46 (3) :831-840.

[7]ZHANG Z, ZOU ZS, FU JL, et al.Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure[J].J Hepatol, 2008, 49 (3) :396-406.

[8] ZHAO J, ZHANG JY, YU HW, et al.Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J].Cell Mol Immunol, 2012, 9 (5) :417-422.

[9]BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterology, 2015, 148 (3) :603-615.

[10]SOLE C, SOLA E, MORALES-RUIZ M, et al.Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis[J].Sci Rep, 2016, 6:32341.

[11]FISCHER J, SILVA TE, SOARES ESP, et al.From stable disease to acute-on-chronic liver failure:Circulating cytokines are related to prognosis in different stages of cirrhosis[J].Cytokine, 2017, 91:162-169.

[12]FAN Z, ENQIANG C, YAO DL, et al.Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virusrelated acute-on-chronic liver failure treated with an artificial liver support system[J].PLo S One, 2017, 12 (4) :e175332.

[13]CHOUDHURY A, KUMAR M, SHARMA BC, et al.Systemic inflammatory response syndrome in acute on chronic liver failure-relevance of'golden window'-a prospective study[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]

[14]GARCIA-MARTINEZ R, ANDREOLA F, MEHTA G, et al.Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J].J Hepatol, 2015, 62 (4) :799-806.

[15]ZHAO J, ZHANG JY, YU HW, et al.Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J].Cell Mol Immunol, 2012, 9 (5) :417-422.

[16]DUAN XZ, LIU FF, TONG JJ, et al.Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure[J].World J Gastroenterol, 2013, 19 (7) :1104-1110.

[17]ROLANDO N, CLAPPERTON M, WADE J, et al.Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure[J].Eur J Gastroenterol Hepatol, 2000, 12 (10) :1135-1140.

[18]KEDARISETTY CK, ANAND L, BHARDWAJ A, et al.Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis[J].Gastroenterology, 2015, 148 (7) :1362-1370.

[19]CHAVEZ-TAPIA NC, MENDIOLA-PASTRANA I, ORNELAS-ARROYO VJ, et al.Granulocyte-colony stimulating factor for acuteon-chronic liver failure:systematic review and meta-analysis[J].Ann Hepatol, 2015, 14 (5) :631-641.

[20]MAO WL, CHEN Y, CHEN YM, et al.Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange[J].J Clin Gastroenterol, 2011, 45 (6) :551-555.

[21]FINKENSTEDT A, NACHBAUR K, ZOLLER H, et al.Acute-on-chronic liver failure:excellent outcomes after liver transplantation but high mortality on the wait list[J].Liver Transpl, 2013, 19 (8) :879-886.

[22]BANARES R, NEVENS F, LARSEN FS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure:the RELIEF trial[J].Hepatology, 2013, 57 (3) :1153-1162.

[23]CUI L, SHI Y, HAN Y, et al.Immunological basis of stem cell therapy in liver diseases[J].Expert Rev Clin Immunol, 2014, 10 (9) :1185-1196.

[24]LIN BL, CHEN JF, QIU WH, et al.Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure:a randomized controlled trial[J].Hepatology, 2017, 66 (1) :209-219.

[25]LI YH, XU Y, WU HM, et al.Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir:a 24-month prospective study[J].Stem Cell Rev, 2016, 12 (6) :645-653.

[26]YANG H, OCHANI M, LI J, et al.Reversing established sepsis with antagonists of endogenous high-mobility group box 1[J].Proc Natl Acad Sci U S A, 2004, 101 (1) :296-301.

[27]LI X, WANG LK, WANG LW, et al.Blockade of high-mobility group box-1 ameliorates acute on chronic liver failure in rats[J].Inflamm Res, 2013, 62 (7) :703-709.

[28] BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterology, 2015, 148 (3) :603-615.

施引文献

资源附件(0)

访问统计